SandipPravinPatelMDProfessor(He/Him)

Oncology • La Jolla, CA

Hematologic Oncology, Thoracic Cancer, Clinical Informatics

Leader, Experimental Therapeutics Deputy Director, San Diego Center for Precision Immunotherap

Join to view full profile

Dr. Patel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Patel's full profile

Already have an account?

Office
3855 Health Sciences Drive
La Jolla, CA 92093
Phone+1 858-822-6580

Fax+1 858-822-6186
Is this information wrong?

Summary

Early phase clinical trials of cancer immunotherapy, solid tumor cellular therapy, thoracic immunooncology, spatial immune profiling, irAEs

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 2011 - 2014
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2008 - 2011
Baylor College of MedicineClass of 2008
Duke UniversityBA, Political Science, Magna Cum Laude, 2000 - 2004

Certifications & Licensure

CA State Medical License 2009 - 2025
NC State Medical License 2011 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Commendation for Excellence in Medical Student Teaching 2008 - 2009, 2009
“Most Awards” Award 2008 - 2009, 2009
Dean’s List 2000 - 2001, 2000 - 2002, 2002
Dean’s List w/t Distinction 2002
Killson Educational Foundation Scholarship
Phi Beta Kappa National Academic Honor Society
Pi Sigma Alpha National Political Science Honor Society
Goldwater Scholarship semifinalist for Duke University
National Merit Scholarship Winner, National Advanced Placement Scholar with Distinction High School
National Qualifier for Quiz Bowl, Fourth place at national TEAMS engineering contest, State Qualifier for Debate
Join now to see all

Clinical Trials

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer Start of enrollment: 2012 Jun 01
Completed
Phase 1, Phase 2
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma Start of enrollment: 2015 Jan 01
Completed
Phase 1, Phase 2
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread Start of enrollment: 2016 Apr 14
Completed
Phase 1, Phase 2
An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2016 May 09
Terminated
Phase 2
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Start of enrollment: 2017 Jan 30
Active, not recruiting
Phase 2
An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed Start of enrollment: 2018 Apr 05
Terminated
Phase 1
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine Start of enrollment: 2018 Aug 29
Completed
Phase 1, Phase 2
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC Start of enrollment: 2018 Dec 27
Active, not recruiting
Phase 1
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2022 Apr 14
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Start of enrollment: 2020 Jul 22
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Immuno-Oncology: New Insights into Targets and Therapies.
White, M., Schokrpur, S., Roland, C., Patel, S.> ;Surgical Oncology Clinics of North America. 2024 Apr 1
SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer.
Guadarrama, E., Ferri, W., Othus, M., Lopez, G., Patel, S., Chae, Y., Dennis, M., Powers, B., Liao, C., George, T., Sharon, E., Ryan, C., Blanke, C., Kurzrock, R.> ;Cancer. 2024 Feb 15
1 citations
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.
Alonso-Gordoa, T., Banerjee, S., Wang, D., Standifer, N., Palmer, D., Cheng, L., Kourtesis, P., Ascierto, M., Das, M., Diamond, J., Patel, S., Naidoo, J., Hellmann, M....> ;Journal for Immunotherapy of Cancer. 2024 Feb 2
Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial.
Othus, M., Chae, Y., Dietrich, E., Streicher, H., Patel, S., Sharon, E., Kurzrock, R.> ;Journal of the National Cancer Institute. 2024 Jan 18
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia.
Megan Othus, David Mutch, Wolfram Samlowski, Elad Sharon, Gabby Lopez, Melissa Plets, Patel, S., Chae, Y., Dennis, M., Gordon, S., Robinson, W., Ryan, C., Blanke, C., ...> ;Clinical Cancer Research. 2024 Jan 5
Germline DNA damage response gene mutations as predictive biomarkers of immune checkpoint inhibitor efficacy.
Michael J Dennis, Sophia Bylsma, Lisa Madlensky, Meghana S Pagadala, Hannah Carter, Sandip P Patel> ;Frontiers in Immunology. 2024 Jan 1
1 citations
Pancreatic ductal adenocarcinoma induces neural injury that promotes a transcriptomic and functional repair signature by peripheral neuroglia.
Jonathan Weitz, Bharti Garg, Alexei Martsinkovskiy, Sandip Patel, Herve Tiriac, Andrew M Lowy> ;Oncogene. 2023 Aug 1
21 citations
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Marcelo V Negrao, Haniel A Araujo, Giuseppe Lamberti, Alissa J Cooper, Neal S Akhave, Teng Zhou, Lukas Delasos, J Kevin Hicks, Mihaela Aldea, Gabriele Minuti, Jacobi H...> ;Cancer Discovery. 2023 Jul 7
6 citations
Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response.
Meghana Pagadala, Timothy J Sears, Victoria H Wu, Eva Pérez-Guijarro, Hyo Kim, Andrea Castro, James V Talwar, Cristian Gonzalez-Colin, Steven Cao, Benjamin J Schmiedel...> ;Nature Communications. 2023 May 12
12 citations
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.
Johanna Bendell, Patricia LoRusso, Michael Overman, Anne M Noonan, Dong-Wan Kim, John H Strickler, Sang-We Kim, Stephen Clarke, Thomas J George, Peter S Grimison, Mina...> ;Cancer Immunology, Immunotherapy. 2023 Jul 1
8 citations
CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report.
Dong-Wan Kim, Sang-We Kim, D Ross Camidge, Catherine A Shu, Kristen A Marrone, Xiuning Le, Collin M Blakely, Keunchil Park, Gee-Chen Chang, Sandip Pravin Patel, Gozde ...> ;Journal of Thoracic Oncology. 2023 May 1
3 citations
Genomic Immune Evasion: Diagnostic and Therapeutic Opportunities in Head and Neck Squamous Cell Carcinomas.
Kedar Kirtane, Maie St John, Harry Fuentes-Bayne, Sandip P Patel, Armen Mardiros, Han Xu, William Y Go, Deborah J Wong, John B Sunwoo, John S Welch, Ng, E., Eric W Ng> ;Journal of Clinical Medicine. 2022 Dec 7
6 citations
The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study.
David J Benjamin, Shuai Chen, Joanna B Eldredge, Shiruyeh Schokrpur, Debory Li, Zhikuan Quan, Jason W Chan, Amy L Cummings, Megan E Daly, Jonathan W Goldman, Matthew A...> ;JTO Clinical and Research Reports. 2022 Dec 1
28 citations
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN).
Jair Bar, Nir Peled, Shiruyeh Schokrpur, Mirjana Wolner, Ofer Rotem, Nicolas Girard, Frank Aboubakar Nana, Sofie Derijcke, Waleed Kian, Sandip Patel, Hadas Gantz-Sorot...> ;Journal of Thoracic Oncology. 2023 Feb 1
124 citations
Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions.
Lian Narunsky-Haziza, Gregory D Sepich-Poore, Ilana Livyatan, Omer Asraf, Cameron Martino, Deborah Nejman, Nancy Gavert, Jason E Stajich, Guy Amit, Antonio González, S...> ;Cell. 2022 Sep 29
8 citations
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity.
Sophia Bylsma, Karen Yun, Sandip Patel, Michael J Dennis> ;Current Treatment Options in Oncology. 2022 Sep 1
4 citations
Improved survival in cervical cancer patients receiving care at National Cancer Institute-designated cancer centers.
Corinne McDaniels-Davidson, Christine H Feng, Maria Elena Martinez, Alison J Canchola, Scarlett Lin Gomez, Jesse N Nodora, Sandip P Patel, Arno J Mundt, Jyoti S Mayadev> ;Cancer. 2022 Oct 1
Resistance to EGFR Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer via Newly Acquired Targetable Oncogenic Driver Alterations With an Emphasis on: Case...
Nicholas P Giustini, Sandip Pravin Patel, Nathaniel J Myall, José Fernando do Prado Moura, Amit Kulkarni, Richard C Chao, Heather Wakelee, Lyudmila Bazhenova> ;JCO Precision Oncology. 2022 Aug 1
4 citations
Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer.
Yinjie Gao, Michelle M Stein, Matthew Kase, Amy L Cummings, Ramit Bharanikumar, Denise Lau, Edward B Garon, Sandip P Patel> ;Cancer Immunology, Immunotherapy. 2023 Feb 1
Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer.
Ruifeng Chen, Kasim Hakimi, Xinlian Zhang, Karen Messer, Sandip Pravin Patel> ;The Oncologist. 2022 Sep 2
8 citations
Clinicopathologic and molecular characteristics of-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy.
Li Yu, Lyudmila Bazhenova, Kathryn Gold, Lisa Tran, Van Hilburn, Peter Vu, Sandip Pravin Patel> ;Translational Lung Cancer Research. 2022 Mar 1
53 citations
Disparities in telemedicine during COVID-19.
Alexander S Qian, Melody K Schiaffino, Vinit Nalawade, Lara Aziz, Fernanda V Pacheco, Bao Nguyen, Peter Vu, Sandip P Patel, Maria Elena Martinez, James D Murphy> ;Cancer Medicine. 2022 Feb 1
7 citations
Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer.
David S Hong, Ajay K Gopal, Alexander N Shoushtari, Sandip P Patel, Aiwu R He, Toshihiko Doi, Suresh S Ramalingam, Amita Patnaik, Shahneen Sandhu, Ying Chen, Craig B D...> ;Frontiers in Immunology. 2022 Jan 1
5 citations
CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung Cancer.
Claire Olingy, Ahmad Alimadadi, Daniel J Araujo, David Barry, Norma A Gutierrez, Max Hardy Werbin, Edurne Arriola, Sandip Pravin Patel, Christian H Ottensmeier, Huy Q ...> ;Frontiers in Immunology. 2022 Jan 1
19 citations
Disparities and trends in the participation of minorities, women, and the elderly in breast, colorectal, lung, and prostate cancer clinical trials.
Juan Javier-Desloges, Tyler J. Nelson, James D. Murphy, Rana R. McKay, Elizabeth Pan, J Kellogg Parsons, Christopher J. Kane, A. Karim Kader, Ithaar Derweesh, Jesse No...> ;Cancer. 2021 Nov 22
Join now to see all

Abstracts/Posters

Photocrosslinkable Polymers for Biomedical Applications.
Grinstaff MW, Carnahan PS, Fleming DL, Hatchell NR, Luman MT, Patel SP, 222nd American Chemical Society
Abstract #896 appears in Blood, Volume 106, issue 11.
Travel grant recipient and poster presentation, American Society of Hematology Conference 2005
Empiric treatment as a means of diagnosis in AIDS patients with CNS lesions.
Poster Presentation, Society of General Internal Medicine Conference 2009

Lectures

SWOG 1609 (DART): A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Genomic Profiling for Lung Cancer: Improving Access to This Important ToolApril 12th, 2023
How Fungi May Open up New Doors for Cancer Diagnosis, TreatmentOctober 3rd, 2022
Melanoma: New Potential Treatment Using Immune Cells Is AnnouncedSeptember 15th, 2022
Join now to see all